References of "Rabenda, Véronique"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDirect and indirect costs attributable to osteoarthritis in active subjects
Rabenda, Véronique ULg; Manette, C.; Lemmens, R. et al

in Journal of Rheumatology (2006), 33(6), 1152-1158

OBJECTIVE: To estimate the direct and indirect costs of osteoarthritis (OA) in an active population, and to identify factors significantly influencing these expenditures. METHODS: A cohort of 3,440 ... [more ▼]

OBJECTIVE: To estimate the direct and indirect costs of osteoarthritis (OA) in an active population, and to identify factors significantly influencing these expenditures. METHODS: A cohort of 3,440 subjects employed by the Liege City Council was followed prospectively for 6 months. Subjects were asked to report monthly OA related health resource utilization (contacts with health professionals, medical examinations, drug consumption, etc.) and absence from work. Health related quality of life (HRQOL) was evaluated at baseline using the Medical Outcomes Study Short-form 36 (SF-36). Logistic regression analysis identified factors associated with the probability that the individual incurred costs, and multiple regression identified factors influencing the magnitude of these costs. RESULTS: A total of 1,811 subjects filled in at least one questionnaire (response rate 52%). The mean duration of followup was 3.46 months. Self-reported prevalence of OA was 34.1%. The mean total direct costs were 44.5 euros per OA patient-month. Contacts with health professionals, medical examinations, drugs, and hospital stays accounted for 23.7 euros, 8.7 euros, 6.7 euros, and 4.9 euros, respectively, per OA patient-month. The average number of sick-leave days was 0.8 per OA patient-month. From a payer's perspective, this loss of productivity represented a mean cost of 64.5 euros per OA patient-month. We also recorded 0.02 mean days off work per active subject-month due to informal care by relatives, yielding a mean cost of 1.8 euro per active subject-month for the employer. Poorer scores for most of the dimensions of the SF-36 at baseline were significantly associated with greater likelihood of incurring direct and indirect costs and with higher costs among subjects who reported costs. If we consider the overall cohort of active subjects, the burden of OA related to the direct and indirect costs was 15.2 euros and 23.8 euros, respectively, per active subject-month. CONCLUSION: Direct and indirect costs attributable to OA are substantial, with productivity related costs being predominant. Poorer HRQOL was a major determinant of these expenditures. [less ▲]

Detailed reference viewed: 47 (7 ULg)
Full Text
Peer Reviewed
See detailAdherence, patient preference and dosing frequency: Understanding the relationship
Reginster, Jean-Yves ULg; Rabenda, Véronique ULg; Neuprez, A.

in BONE (2006), 38(4 Suppl 1), 2-6

Adherence to treatment among patients with chronic diseases is currently suboptimal. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications and therefore increased ... [more ▼]

Adherence to treatment among patients with chronic diseases is currently suboptimal. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications and therefore increased healthcare costs. For patients with osteoporosis, long-term adherence to therapy is further complicated by the asymptomatic nature of the disease and the lack of options for patient self-monitoring. Bone densitometry and biochemical markers of bone turnover are assessments that could be used by physicians to provide feedback to patients on the effectiveness of medication. However, these feedback systems are costly and not readily available. Oral bisphosphonates are currently the first-line therapy for postmenopausal osteoporosis. However, they are associated with stringent dosing procedures, and some patients may experience upper gastrointestinal side-effects following administration. Alarmingly, approximately 50% of patients discontinue daily bisphosphonate therapy within 1 year, which negatively impacts upon treatment outcomes, leading to a reduced antifracture effect. Thus, there is a need for an effective therapy that enhances patient adherence. The impact of reducing bisphosphonate dosing frequency on therapeutic adherence has been documented in several studies. Data have shown that, although weekly dosing improves adherence compared with daily administration, levels are still suboptimal. Results from two recent studies that have assessed patient preference for a once-monthly compared with a weekly dosing schedule have demonstrated that patients prefer a monthly regimen (67-71%). Their reasons for preferring once-monthly dosing were that it would fit better with their lifestyle (49-77%) and would be more convenient (75%). A novel once-monthly bisphosphonate regimen, such as the ibandronate regimen, may therefore help patients to follow dosing guidelines and encourage them to stay on therapy longer, thereby improving overall therapy effectiveness. [less ▲]

Detailed reference viewed: 33 (4 ULg)
Full Text
Peer Reviewed
See detailPatient Preference in the Management of Postmenopausal Osteoporosis with Bisphosphonates
Reginster, Jean-Yves ULg; Rabenda, Véronique ULg

in Clinical Interventions in Aging (2006), 1(4), 415-23

The leading treatments for postmenopausal osteoporosis are the nitrogen-containing bisphosphonates, which are required long term for optimal benefit. Oral bisphosphonates have proven efficacy in ... [more ▼]

The leading treatments for postmenopausal osteoporosis are the nitrogen-containing bisphosphonates, which are required long term for optimal benefit. Oral bisphosphonates have proven efficacy in postmenopausal osteoporosis in clinical trials, but in practice the therapeutic benefits are often compromised by patients' low adherence. Nonadherence to bisphosphonate therapy negatively impacts outcomes such as fracture rate; fractures are in turn associated with decreased quality of life. The most common reason cited by patients for their nonadherence is that the strict dosing instructions for bisphosphonates are difficult to follow. One aspect of bisphosphonate administration that can be changed is dosing frequency and several studies have evaluated patient preferences for different dosing schedules. Studies have shown a preference for a weekly bisphosphonate regimen versus daily dosing and it has been demonstrated that this preference for reduced dosing frequency impacts on adherence. Ibandronate is the first nitrogen-containing oral bisphosphonate for osteoporosis that can be administered in a monthly regimen and two robust clinical studies demonstrated a strong patient preference for this monthly regimen versus a weekly regimen. It is important that physicians consider patient preference when prescribing treatment for osteoporosis to ensure that the disease is effectively managed for the long-term benefit of the patient. [less ▲]

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailAdherence to anti-osteoporotic treatment: does it really matter?
Reginster, Jean-Yves ULg; Rabenda, Véronique ULg

in Future Rheumatology (2006), 1

Detailed reference viewed: 5 (3 ULg)
Full Text
Peer Reviewed
See detailObservance et persistance: impact sur l'efficience des traitements de l'osteoporose
Reginster, Jean-Yves ULg; Rabenda, Véronique ULg

in Revue Médicale Suisse (2005), 1(35), 2278-81

Low adherence to therapies has been repeatedly described as a major determinant of poor clinical outcomes in chronic disorders. Bisphosphonates, the most widely prescribed drugs in this field, have been ... [more ▼]

Low adherence to therapies has been repeatedly described as a major determinant of poor clinical outcomes in chronic disorders. Bisphosphonates, the most widely prescribed drugs in this field, have been linked to a 12-month persistence lower than 40%. The situation is improved when using the weekly formulation compared to the daily intake of the drug. Low compliance results in lesser increase in bone mineral density and decreased anti-fracture efficacy. New medications, currently developed for the management of osteoporosis, will be user-friendly, allowing to an improvement of compliance and persistence. [less ▲]

Detailed reference viewed: 61 (8 ULg)
Full Text
Peer Reviewed
See detailGlobal prevalence and skeletal implications of vitamin D inadequacy
Reginster, Jean-Yves ULg; Richy, Florent; Rabenda, Véronique ULg et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 362

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailA naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal antiinflammatory drugs
Rabenda, Véronique ULg; Burlet, N.; Ethgen, Olivier ULg et al

in Annals of the Rheumatic Diseases (2005), 64(5), 688-693

OBJECTIVES: To capture changes in the quality of life (QoL) occurring in patients with osteoarthritis (OA) during treatment with non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and to identify ... [more ▼]

OBJECTIVES: To capture changes in the quality of life (QoL) occurring in patients with osteoarthritis (OA) during treatment with non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and to identify factors that predict such changes. METHODS: A naturalistic, prospective follow up of 783 patients with OA in whom primary care physicians decided to start treatment with non-selective NSAIDs. Short Form-36 (SF-36) and the Western Ontario and McMaster Universities OA index (WOMAC) were assessed at baseline and after 3 months. Baseline results were compared with QoL values in 4800 subjects randomly selected from the general population. Multiple regression analysis was performed to identify determinants of QoL at baseline and measures influencing changes in SF-36 or WOMAC during follow up. RESULTS: All QoL dimensions were significantly (p<0.01) decreased in patients with OA compared with controls. Significant improvement (p<0.05) in four dimensions of the SF-36 (vitality, role emotional, role physical, bodily pain) and in all components of the WOMAC was seen between baseline and month 3. Older age, female sex, longer duration of OA, and a higher number of comorbidities were the major determinants of a poor QoL at baseline. Maximal benefit from non-specific NSAIDs was seen in patients with the most severe impairment in QoL and the shortest duration of OA. CONCLUSION: OA negatively impacts all dimensions of the QoL. Non-specific NSAIDs improve the QoL in patients with OA treated in a "real life setting". The profile of patients receiving maximal benefit from such treatment may be of interest for health providers, enabling them to decide who should preferentially be given cytoprotective treatments or coxibs. [less ▲]

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailPrevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects
Rabenda, Véronique ULg; Manette, Christelle; Lemmens, Régine et al

in Osteoporosis International (2005, March), 16(Suppl.3), 110

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailImpact of health professionals utilization induced by musculoskeletal disorders among active subjects
Rabenda, Véronique ULg; Manette, Christelle; Lemmens, Régine et al

in Osteoporosis International (2005, March), 16(Suppl.3), 110

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailVitamin D inadequacy: global prevalence and skeletal implications
Reginster, Jean-Yves ULg; Richy, Florent; Rabenda, Véronique ULg et al

in Osteoporosis International (2005, March), 16(Suppl.3), 64

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailIndirect costs induced by osteoarthritis and osteoporosis in the workplace
Rabenda, Véronique ULg; MANETTE, Christine ULg; Lemmens, R. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 13-14

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailVitamin D inadequacy : global prevalence and skeletal implications
Reginster, Jean-Yves ULg; Richy, F.; Rabenda, Véronique ULg et al

in BONE (2005), 36(S2), 462

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailIs there any interest in combining treatments in osteoporosis?
Rabenda, Véronique ULg; Hanssens, Linda; De Ceulaer, Frédéric et al

in Current Rheumatology Reviews (2005), 1

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailTime dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach
Richy, F.; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Annals of the Rheumatic Diseases (2004), 63(7), 759-766

OBJECTIVES: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. METHODS: An ... [more ▼]

OBJECTIVES: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. METHODS: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse effects, publication range January 1985 to January 2003. The publications retrieved were assessed during a specifically dedicated WHO meeting including leading experts in all related fields. Statistics were performed conservatively. Meta-regression was performed by regressing NSAID adjusted estimates against study duration categories. RESULTS: Among RCT data, indolic derivates provided a significantly higher risk of GI complications related to NSAID use than for non-users: RR = 2.25 (1.00; 5.08) than did other compounds: naproxen: RR = 1.83 (1.25; 2.68); diclofenac: RR = 1.73 (1.21; 2.46); piroxicam: RR = 1.66 (1.14; 2.44); tenoxicam: RR = 1.43 (0.40; 5.14); meloxicam: RR = 1.24 (0.98; 1.56), and ibuprofen: RR = 1.19 (0.93; 1.54). Indometacin users had a maximum relative risk for complication at 14 days. The other compounds presented a better profile, with a maximum risk at 50 days. Significant additional risk factors included age, dose, and underlying disease. The controlled cohort studies provided higher estimates: RR = 2.22 (1.7; 2.9). Publication bias testing was significant, towards a selective publication of deleterious effects of NSAIDs from small sized studies. CONCLUSION: This meta-analysis characterised the "compound" and "time" aspects of the GI toxicity of non-selective NSAIDs. The risk/benefit ratio of such compounds should thus be carefully and individually evaluated at the start of long term treatment. [less ▲]

Detailed reference viewed: 48 (10 ULg)
Full Text
Peer Reviewed
See detailTime-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach
Richy, Florent; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 9

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailImpact of osteoarthritis and chronic back pain on health-related quality of life among patients on NSAIDS
Rabenda, Véronique ULg; Ethgen, Olivier ULg; Belaiche, Jacques ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 89-90

Detailed reference viewed: 4 (0 ULg)